Conference Coverage

Oral paclitaxel bests IV version for tumor response, neuropathy incidence in mBC

Publish date: December 19, 2019

 

REPORTING FROM SABCS 2019

SOURCE: Umanzor G et al. SABCS 2019, Abstract GS6-01.

Pages

Recommended Reading

APHINITY 6-year data: Benefit ongoing in HER2+ early BC, no significant OS benefit
MDedge Hematology and Oncology
Promising new neoadjuvant strategy in luminal B breast cancer
MDedge Hematology and Oncology
Pembrolizumab plus chemo boosts pCR rate in TNBC
MDedge Hematology and Oncology
TNBC: Adding capecitabine boosts disease-free survival in prospective trial
MDedge Hematology and Oncology
Residual cancer burden linked to long-term survival
MDedge Hematology and Oncology
CTS5 score partially validated for predicting late distant breast cancer recurrences
MDedge Hematology and Oncology
ctDNA, CTCs predict TNBC relapse – now what?
MDedge Hematology and Oncology
First report from NeoTRIPaPDL1: No pCR benefit with atezolizumab in TNBC
MDedge Hematology and Oncology
TNBC: Weekly nab-paclitaxel delivers, denosumab disappoints
MDedge Hematology and Oncology
PEARL lacks luster in metastatic breast cancer progressing on AIs
MDedge Hematology and Oncology